Source: PHARMAC
Pharmac is proposing to fund silver diamine fluoride for people accessing dental services through Health New Zealand public hospitals, and ‘Health New Zealand’s Community Oral Health Service’ for children and some adolescents.
Silver diamine fluoride is a topical treatment that halts the progression of tooth decay and reduces tooth sensitivity. It comes in a liquid form that is applied to the tooth, making it less painful and invasive than a filling.
It can be especially helpful for children, elderly patients and those who may find some traditional dental procedures challenging, such as people who are sensitive to noise.
People who access ‘Health New Zealand’s Community Oral Health Service’ would be eligible for this treatment under this proposal. These community services are predominantly for children; some adolescents are also eligible.
People of all ages accessing Health New Zealand hospital dental services, both inpatient and outpatient, would also be eligible for this treatment.
Adrienne Martin, Pharmac’s Director Pharmaceuticals says, “this is good news for children and those having dental treatment in hospitals who need an alternative option to traditional dental care.”
“We hope it takes some of the anxiety away for children with a real fear of going to the dentist, as well as the parents and caregivers who care for them.”
Pharmac wants to know what people think about this proposal. Feedback can be provided through Pharmac’s website until Thursday 30 October.
Following public consultation, Pharmac will make a decision on the funding proposal. If approved, it will be funded from 1 December 2025.
